Company develops significant visibility enhancements of subtle lesions independent of breast density; demonstrating at RSNA 2014 November 30 – December 5th
Stockholm, Sweden – November 17, 2014 – ContextVision, the leading provider of image processing software, today released GOPView® Mammo3, a complete mammography image processing product for both screening and diagnostic imaging. In an industry continually facing demands for high image quality, ContextVision is providing the ability to see small variations in breast tissue unlike any other product on the market.
GOPView Mammo3 provides high transparency of the parenchyma and superior visibility of subtle lesions and micro calcifications independent of breast density. This is enabled by the product’s high global and local contrast in combination with intelligent noise suppression. Through this image processing of both screening and diagnostic images, doctors are better able to make fast and accurate diagnoses.
“As radiologists working at a specialist clinic we need to be able to read mammography images without compromising the accuracy of the diagnosis,” said MD Jonas Kierkegaard and MD Hans Lundquist, Bröstcentrum City, Stockholm, Sweden. “The perfect mammogram provides clear micro calcifications and a transparency of the parenchyma to ensure confidence in finding subtle lesions. A well-balanced, harmonic image helps us in reading mammograms day after day without getting eye fatigue.”
GOPView Mammo3 responds directly to the market demand for high-quality diagnostic imaging capabilities. It provides optimal image quality and offers the feature to be customized according to individual preferences and regional markets.
“Women deserve a diagnostic process that provides their medical examiners with the proper image quality to make a better-informed diagnosis,” said Anita Tollstadius, CEO at ContextVision. “In the U.S. alone, more than 40 percent of women have denser breast tissue. It is imperative that mammography equipment is able to address this challenge as increased density often lowers the sensitivity of mammography. In using ContextVision’s software, doctors are better able to discern harmless dense breast tissue from problematic lesions and act accordingly to ensure active response.”
For more information about ContextVision’s products go to www.contextvision.com, or visit ContextVision at RSNA 2014 in Chicago, North Hall B, booth #7210.
ContextVision’s technology provides doctors with improved images, which are crucial for accurate diagnosis and treatment. ContextVision is the industry leader in medical image analysis and enhancement software, with more than 150,000 installations worldwide through its OEM customers. The company started out as an industry pioneer more than 30 years ago, and is today developing the next generation of medical imaging software for 2D/3D/4D ultrasound, MRI, X-Ray, mammography and CT. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com